Last reviewed · How we verify
ShigETEC live, attenuated, oral vaccine
ShigETEC live, attenuated, oral vaccine is a Biologic drug developed by Eveliqure Biotechnologies GmbH. It is currently in Phase 1 development.
At a glance
| Generic name | ShigETEC live, attenuated, oral vaccine |
|---|---|
| Sponsor | Eveliqure Biotechnologies GmbH |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- ShigETEC Vaccine Study in Bangladesh (PHASE1)
- Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old (PHASE2)
- Phase 1 Trial for Safety, Tolerability, and Immunogenicity of a Live, Attenuated, Oral Shigella/ETEC Combination Vaccine to Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ShigETEC live, attenuated, oral vaccine CI brief — competitive landscape report
- ShigETEC live, attenuated, oral vaccine updates RSS · CI watch RSS
- Eveliqure Biotechnologies GmbH portfolio CI
Frequently asked questions about ShigETEC live, attenuated, oral vaccine
What is ShigETEC live, attenuated, oral vaccine?
ShigETEC live, attenuated, oral vaccine is a Biologic drug developed by Eveliqure Biotechnologies GmbH.
Who makes ShigETEC live, attenuated, oral vaccine?
ShigETEC live, attenuated, oral vaccine is developed by Eveliqure Biotechnologies GmbH (see full Eveliqure Biotechnologies GmbH pipeline at /company/eveliqure-biotechnologies-gmbh).
What development phase is ShigETEC live, attenuated, oral vaccine in?
ShigETEC live, attenuated, oral vaccine is in Phase 1.